Biotechnology · Brisbane, California, United States
$0.99
-2.62% (-$0.03)2026-07-09
Smart-Money SignalNeutral · 54/100— Insider open-market flow is flat over 90 days
Net Income-$27.7M
EPS$-2.53
Market Cap$14.2M
Price Performance
Historical data including institutional events
Company Profile
M
Matthew Angel
CEO & Executive Director
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study.
Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
